Combinatorial drug therapy for cancer in the post-genomic era

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · see citing works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574 · see citing works

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237 · see citing works

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · see citing works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works

Abiraterone and Increased Survival in Metastatic Prostate Cancer

de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · see citing works

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works

The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored

Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A. C., Mínguez, P., Doerks, T., Stark, M., Muller, J., Peer Bork, B., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq973 · Cited by 3,460 · see citing works

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

Juliano, R. L., & Ling, V. W. T. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,317 · see citing works

A census of human cancer genes

Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · see citing works

Clonal evolution in cancer

Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162 · see citing works

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Mechanisms of Cancer Drug Resistance

Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · see citing works

Tumour evolution inferred by single-cell sequencing

Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598 · see citing works

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445 · see citing works

The Database of Interacting Proteins: 2004 update

Salwinski, L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh086 · Cited by 2,271 · see citing works

Global cancer transitions according to the Human Development Index (2008–2030): a population-based study

Bray, F., Jemal, A., Grey, N., Ferlay, J., & Forman, D. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70211-5 · Cited by 2,225 · see citing works

The Genetic Landscape of a Cell

Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162 · see citing works

Chemotherapy and the war on cancer

Chabner, B. A., & Roberts, T. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1529 · Cited by 2,152 · see citing works

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · see citing works

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works

Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

Joensuu, H., Roberts‎, P., Sarlomo‐Rikala, M., Andersson, L. C., Tervahartiala, P. O., Tuveson, D. A., Silberman, S., Capdeville, R., Dimitrijević, S., Druker, B. J., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,030 · see citing works

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958 · see citing works

Believe it or not: how much can we rely on published data on potential drug targets?

Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888 · see citing works

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · see citing works

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,818 · see citing works

Addiction to Oncogenes--the Achilles Heal of Cancer

Weinstein, I. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,753 · see citing works

Reactome: a database of reactions, pathways and biological processes

Croft, D., O'Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy, M., Garapati, P., Gopinath, G., Jassal, B., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1018 · Cited by 1,751 · see citing works

Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data

Sachs, K., Perez, O. D., Pe’er, D., Lauffenburger, D. A., & Nolan, G. P. (2005) · Science · doi:10.1126/science.1105809 · Cited by 1,724 · see citing works

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627 · see citing works

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,608 · see citing works

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, É., Elisei, R., Jarząb, B., Vasselli, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,556 · see citing works

Cancer Research Communications

Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Martini, P., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., Di Marino, M., et al. (2021) · doi:10.1158/1078-0432 · Cited by 1,537 · see citing works

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,468 · see citing works

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460 · see citing works

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · see citing works

Guidelines for the welfare and use of animals in cancer research

Workman, P., Aboagye, E. O., Balkwill, F. R., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J. I., Farningham, D. A. H., Glennie, M. J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605642 · Cited by 1,449 · see citing works

DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance

DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

Personal omics profiling reveals dynamic molecular and medical phenotypes

Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.009 · Cited by 1,291 · see citing works

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199 · see citing works

Systems Biology and New Technologies Enable Predictive and Preventative Medicine

Hood, L., Heath, J. R., Phelps, M. E., & Lin, B. (2004) · Science · doi:10.1126/science.1104635 · Cited by 1,108 · see citing works

Pathway Commons, a web resource for biological pathway data

Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1039 · Cited by 1,101 · see citing works

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063 · see citing works

Treatment for Adult HIV Infection

Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M., Carpenter, C. C. J., Fischl, M. A., Gazzard, B., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,034 · see citing works

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · see citing works

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993 · see citing works

A human phenome-interactome network of protein complexes implicated in genetic disorders

Lage, K., Karlberg, E., Størling, Z. M., Olason, P., Pedersen, A., Rigina, O., Hinsby, A., Tümer, Z., Pociot, F., Tommerup, N., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1295 · Cited by 973 · see citing works

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 960 · see citing works

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 940 · see citing works

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 903 · see citing works

Histone Deacetylase Inhibitors in Cancer Therapy

Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 880 · see citing works

The BioGRID Interaction Database: 2011 update

Stark, C., Breitkreutz, B., Chatr‐aryamontri, A., Boucher, L., Oughtred, R., Livstone, M. S., Nixon, J., Auken, K. M. V., Wang, X., Shi, X., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1116 · Cited by 854 · see citing works

Oncogene Addiction

Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805 · see citing works

Genetic variegation of clonal architecture and propagating cells in leukaemia

Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S., Kempski, H. M., Moorman, A. V., Titley, I., Swansbury, J. G., et al. (2010) · Nature · doi:10.1038/nature09650 · Cited by 803 · see citing works

Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies

Shah, O. J., Wang, Z., & Hunter, T. R. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 800 · see citing works

Multicomponent therapeutics for networked systems

Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769 · see citing works

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732 · see citing works

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 681 · see citing works

The IntAct molecular interaction database in 2010

Aranda, B., Achuthan, P., Alam-Faruque, Y., Armean, I., Bridge, A., Derow, C., Feuermann, M., Ghanbarian, A. T., Kerrien, S., Khadake, J., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp878 · Cited by 620 · see citing works

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

Nahta, R., Hung, M., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607 · see citing works

Shape-Dependent Control of Cell Growth, Differentiation, and Apoptosis: Switching between Attractors in Cell Regulatory Networks

Huang, S., & Ingber, D. E. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.5044 · Cited by 606 · see citing works

BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models

Li, C., Donizelli, M., Rodriguez, N., Dharuri, H., Endler, L., Chelliah, V., Li, L., He, E., Henry, A., Stefan, M. I., et al. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-92 · Cited by 597 · see citing works

Next-generation genomics: an integrative approach

Hawkins, R. D., Hon, G. C., & Ren, B. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2795 · Cited by 591 · see citing works

PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation

Hornbeck, P. V., Chabra, I., Kornhauser, J. M., Skrzypek, E., & Zhang, B. (2004) · PROTEOMICS · doi:10.1002/pmic.200300772 · Cited by 590 · see citing works

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 582 · see citing works

The expected effect of a combination of agents: the general solution

Berenbaum, M. C. (1985) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(85)80176-4 · Cited by 524 · see citing works

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 519 · see citing works

Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis

Espinal, M., Kim, S., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 508 · see citing works

MINT, the molecular interaction database: 2009 update

Ceol, A. G. M., Chatr‐aryamontri, A., Licata, L., Peluso, D., Briganti, L., Perfetto, L., Castagnoli, L., & Cesareni, G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp983 · Cited by 507 · see citing works

Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast

Giaever, G. N., Flaherty, P., Kumm, J., Proctor, M. J., Nislow, C., Jaramillo, D. F., Chu, A. M., Jordan, M. I., Arkin, A. P., & Davis, R. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307490100 · Cited by 506 · see citing works

Circumventing cancer drug resistance in the era of personalized medicine

Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503 · see citing works

Intratumor Heterogeneity: Seeing the Wood for the Trees

Yap, T. A., Gerlinger, M., Futreal, P. A., Pusztai, L., & Swanton, C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003854 · Cited by 487 · see citing works

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M. R., Patterson, L., Brandon, A. D. H., Gowan, S. M., Boxall, F. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 481 · see citing works

Predicting selective drug targets in cancer through metabolic networks

Folger, O., Jerby‐Arnon, L., Frezza, C., Gottlieb, E., Ruppin, E., & Shlomi, T. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.35 · Cited by 469 · see citing works

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Apsel, B., Blair, J. A., González, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 452 · see citing works

The Hsp90 molecular chaperone: an open and shut case for treatment

Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447 · see citing works

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442 · see citing works

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 420 · see citing works

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705158104 · Cited by 390 · see citing works

Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing

Campbell, P. J., Pleasance, E., Stephens, P. J., Dicks, E., Rance, R., Goodhead, I., Follows, G., Green, A. R., Futreal, P. A., & Stratton, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801523105 · Cited by 365 · see citing works

DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90

Kèlland, L. R., Sharp, S. Y., Rogers, P., Myers, T. G., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1940 · Cited by 350 · see citing works

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Modi, S., Stopeck, A., Gordon, M. S., Mendelson, D. S., Solit, D. B., Bagatell, R., Ma, W., Wheler, J. J., Rosen, N. X., Norton, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7960 · Cited by 335 · see citing works

Translating cancer research into targeted therapeutics

Bono, J. S. D., & Ashworth, A. (2010) · Nature · doi:10.1038/nature09339 · Cited by 333 · see citing works

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways

Yap, T. A., Omlin, A. G., & Bono, J. S. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 328 · see citing works

Gene Amplification and Drug Resistance in Cultured Murine Cells

SCHIMKE, R. T., Kaufman, R. J., Alt, F. W., & Kellems, R. F. (1978) · Science · doi:10.1126/science.715457 · Cited by 313 · see citing works

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S. A., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 310 · see citing works

Envisioning the future of early anticancer drug development

Yap, T. A., Sandhu, S. K., Workman, P., & Bono, J. S. D. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2870 · Cited by 279 · see citing works

Chemical combination effects predict connectivity in biological systems

Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100116 · Cited by 275 · see citing works

Adaptive clinical trials in oncology

Berry, D. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.165 · Cited by 268 · see citing works

Heat Shock Protein 90 as a Drug Target: Some Like It Hot

Banerji, U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0132 · Cited by 265 · see citing works

Spatio-temporal correlations can drastically change the response of a MAPK pathway

Takahashi, K., Tănase‐Nicola, S., & ten Wolde, P. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906885107 · Cited by 263 · see citing works

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Albain, K. S., Barlow, W. E., Ravdin, P. M., Farrar, W. B., Burton, G. V., Ketchel, S. J., Cobau, C. D., Levine, E. G., Ingle, J. N., Pritchard, K. I., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61523-3 · Cited by 256 · see citing works

Utilizing RNA interference to enhance cancer drug discovery

Iorns, E. J., Lord, C. J., Turner, N. C., & Ashworth, A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2355 · Cited by 251 · see citing works

Development of Novel Combination Therapies

Woodcock, J., Griffin, J. P., & Behrman, R. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1101548 · Cited by 248 · see citing works

Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

George, S., Wang, Q., Heinrich, M. C., Corless, C. L., Zhu, M. J., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Tap, W. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9394 · Cited by 247 · see citing works

Die quantitativen Probleme der Pharmakologie

Loewe, S. (1928) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/bf02322290 · Cited by 245 · see citing works

A global analysis of cross-talk in a mammalian cellular signalling network

Natarajan, M., Lin, K.-M., Hsueh, R. C., Sternweis, P. C., & Ranganathan, R. (2006) · Nature Cell Biology · doi:10.1038/ncb1418 · Cited by 237 · see citing works

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp304 · Cited by 231 · see citing works

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

Iorns, E. J., Turner, N. C., Elliott, R. J. R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N. J., Crook, T., Lord, C. J., & Ashworth, A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.001 · Cited by 230 · see citing works

Clinical Implications of the Cancer Genome

MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 228 · see citing works

Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis

Iadevaia, S., Lu, Y., Morales, F. C., Mills, G. B., & Ram, P. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0460 · Cited by 219 · see citing works

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Reslan, H. B., Ho, C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215 · see citing works

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF

Xing, F., Persaud, Y., Pratilas, C. A., Taylor, B. S., Janakiraman, M., She, Q., Gallardo, H. F., Liu, C., Merghoub, T., Hefter, B., et al. (2011) · Oncogene · doi:10.1038/onc.2011.250 · Cited by 208 · see citing works

Epigenetic biomarkers for human cancer: The time is now

Mulero‐Navarro, S., & Esteller, M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.03.001 · Cited by 205 · see citing works

Anticancer therapy with checkpoint inhibitors: what, where and when?

Garrett, M. D., & Collins, I. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.014 · Cited by 204 · see citing works

Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data

Zhao, X., Iskar, M., Zeller, G., Kuhn, M., van Noort, V., & Peer Bork, B. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002323 · Cited by 201 · see citing works

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Eder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H. N., Cancilla, B., Chu, F., Hitchcock‐Bryan, S., Sherman, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 198 · see citing works

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential22Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Cy, Cyanine; DLCL, diffuse large cell lymphoma; dNTPs, deoxyribonucleotides; ESTs, expressed sequence tags; mRNA, messenger RNA; NHL, non-Hodgkin’s lymphoma; ORF, open reading frame; RT-PCR, reverse transcription-polymerase chain reaction; and 17AAG, 17-allylamino,17-demethoxygeldanamycin.

Clarke, P. A., Poele, R. T., Wooster, R. F., & Workman, P. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00785-7 · Cited by 185 · see citing works

Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency

Wei, G., Margolin, A. A., Haery, L., Brown, E., Cucolo, L., Julian, B., Shehata, S., Kung, A. L., Beroukhim, R., & Golub, T. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.028 · Cited by 185 · see citing works

The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities

Palma, M. D., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 178 · see citing works

From an Ethics of Rationing to an Ethics of Waste Avoidance

Brody, H. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1203365 · Cited by 173 · see citing works

Combination chemical genetics

Lehár, J., Stockwell, B. R., Giaever, G., & Nislow, C. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.120 · Cited by 172 · see citing works

Mechanisms of Resistance to Anticancer Agents

Brockman, R. W. (1963) · Advances in cancer research · doi:10.1016/s0065-230x(08)60983-5 · Cited by 152 · see citing works

Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo

Meng, J., Dai, B., Fang, B., Bekele, B. N., Bornmann, W. G., Sun, D., Peng, Z., Herbst, R. S., Papadimitrakopoulou, V. A., Minna, J. D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014124 · Cited by 146 · see citing works

Comparing Signaling Networks between Normal and Transformed Hepatocytes Using Discrete Logical Models

Sáez-Rodríguez, J., Alexopoulos, L. G., Zhang, M., Morris, M. K., Lauffenburger, D. A., & Sorger, P. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4453 · Cited by 145 · see citing works

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

Solit, D. B., She, Y., Lobo, J. M., Kris, M. G., Scher, H. I., Rosen, N. X., & Sirotnak, F. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1347 · Cited by 132 · see citing works

Open access chemical and clinical probes to support drug discovery

Edwards, A. M., Bountra, C., Kerr, R. S., & Willson, T. M. (2009) · Nature Chemical Biology · doi:10.1038/nchembio0709-436 · Cited by 130 · see citing works

Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes

Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125 · see citing works

Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells

Gaspar, N., Sharp, S. Y., Pacey, S., Jones, C., Walton, M. I., Vassal, G., Eccles, S. A., Pearson, A. D. J., & Workman, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3131 · Cited by 124 · see citing works

Training Signaling Pathway Maps to Biochemical Data with Constrained Fuzzy Logic: Quantitative Analysis of Liver Cell Responses to Inflammatory Stimuli

Morris, M. K., Sáez-Rodríguez, J., Clarke, D. C., Sorger, P. K., & Lauffenburger, D. A. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001099 · Cited by 123 · see citing works

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

Chandarlapaty, S., Scaltriti, M., Angelini, P. D., Ye, Q., Guzmán, M., Hudis, C. A., Norton, L., Solit, D. B., Arribas, J., Baselga, J. M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.337 · Cited by 123 · see citing works

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

Infante, J. R., Falchook, G. S., Lawrence, D. P., Weber, J. S., Kefford, R. F., Bendell, J. C., Kurzrock, R., Shapiro, G. I., Kudchadkar, R. R., Long, G. V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.cra8503 · Cited by 122 · see citing works

Reactome pathway analysis to enrich biological discovery in proteomics data sets

Haw, R., Hermjakob, H., D'Eustachio, P., & Stein, L. (2011) · PROTEOMICS · doi:10.1002/pmic.201100066 · Cited by 117 · see citing works

The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action

Lee, M. S., Johansen, L. M., Zhang, Y., Wilson, A., Keegan, M., Avery, W., Elliott, P. J., Borisy, A. A., & Keith, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2235 · Cited by 115 · see citing works

Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics

Yap, T. A., & Workman, P. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 104 · see citing works

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

Shuttleworth, S. J., Silva, F. A., Cecil, A., Tomassi, C., Hill, T., Raynaud, F. I., Clarke, P. A., & Workman, P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011229 · Cited by 103 · see citing works

Evolution of resistance to anti-cancer therapy during general dosing schedules

Foo, J., & Franziska Michor, A. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.11.022 · Cited by 85 · see citing works

Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor

Moffat, D. F. C., Patel, S. R., Day, F. A., Belfield, A. J., Donald, A., Rowlands, M., Wibawa, J. I. D., Brotherton, D. H., Stimson, L., Clark, V., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101177s · Cited by 81 · see citing works

canSAR: an integrated cancer public translational research and drug discovery resource

Halling‐Brown, M., Bulusu, K. C., Patel, M. N., Tym, J. E., & Al‐Lazikani, B. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr881 · Cited by 81 · see citing works

Life in the Fast Lane: Mammalian Disease Models in the Genomics Era

Dow, L. E., & Lowe, S. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.023 · Cited by 79 · see citing works

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer

Mullenders, J., & Bernards, R. (2009) · Oncogene · doi:10.1038/onc.2009.295 · Cited by 74 · see citing works

A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway

Yan, H., Zhang, B., Li, S., & Zhao, Q. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-50 · Cited by 73 · see citing works

A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl

Choi, H. G., Ren, P., Adrián, F., Sun, F., Lee, H. S., Wang, X., Ding, Q., Zhang, G., Xie, Y., Zhang, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901808w · Cited by 71 · see citing works

Cancer models, genomic instability and somatic cellular Darwinian evolution

Little, M. P. (2010) · Biology Direct · doi:10.1186/1745-6150-5-19 · Cited by 70 · see citing works

A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.

Cosimo, S. D., Bendell, J. C., Cervantes, A. M. R., Roda, D., Prudkin, L., Stein, M. N., Leighton-Swayze, A., Song, Y., Ebbinghaus, S., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3008 · Cited by 67 · see citing works

Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database

Bickerton, G. R., Higueruelo, A. P., & Blundell, T. L. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-313 · Cited by 66 · see citing works

Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy.

Komarova, N. L., & Wodarz, D. (2003) · PubMed · Cited by 66 · see citing works

Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling

Lu, Y., Müller, M. M., Smith, D. M., Dutta, B., Komurov, K., Iadevaia, S., Ruths, D. A., Tseng, J.-T., Yu, S., Yu, Q., et al. (2011) · Oncogene · doi:10.1038/onc.2011.164 · Cited by 65 · see citing works

A Blueprint for Advancing Genetics-Based Cancer Therapy

Sellers, W. R. (2011) · Cell · doi:10.1016/j.cell.2011.09.016 · Cited by 64 · see citing works

Computational modeling of mammalian signaling networks

Hughey, J., Lee, T. K., & Covert, M. W. (2009) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.52 · Cited by 63 · see citing works

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

Meng, J., Peng, H., Dai, B., Guo, W., Wang, L., Ji, L., Minna, J. D., Chresta, C. M., Smith, P. D., Fang, B., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9844 · Cited by 62 · see citing works

Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Mumenthaler, S. M., Foo, J., Leder, K., Choi, N. C., Agus, D. B., Pao, W. J., Mallick, P., & Franziska Michor, A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200270v · Cited by 61 · see citing works

The Emperor of All Maladies

Mukherjee, S. (2010) · Cited by 57 · see citing works

Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside

Rodon, J. A., Pérez-García, J. M., & Kurzrock, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0117 · Cited by 51 · see citing works

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

Kibel, A. S. (2011) · Yearbook of Urology · doi:10.1016/j.yuro.2011.05.029 · Cited by 48 · see citing works

CytoSolve: A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models

Ayyadurai, V. A. S., & Dewey, C. F. (2010) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-010-0143-x · Cited by 43 · see citing works

A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.

Khan, K. H., Yan, L., Mezynski, J., Patnaik, A., Moreno, V., Papadopoulos, K. P., Garrett, C. R., Ong, M., Shannon, K. A., Morosky, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e13599 · Cited by 36 · see citing works

Surface immunoglobulin positive lymphocytes in human breast cancer tissue and homolateral axillary lymph nodes

Richters, A., & Kaspersky, C. L. (1975) · Cancer · doi:10.1002/1097-0142(197501)35:1 · Cited by 35 · see citing works

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.

Tolcher, A. W., Baird, R. D., Patnaik, A., Garcia, V. M., Papadopoulos, K. P., Garrett, C. R., Olmos, D., Shannon, K., Zazulina, V., Rubin, E. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3004 · Cited by 35 · see citing works

Kinetic simulation of anticancer drug interactions

Jackson, R. (1980) · International Journal of Bio-Medical Computing · doi:10.1016/0020-7101(80)90045-8 · Cited by 28 · see citing works

ROCK: a breast cancer functional genomics resource

Sims, D., Bursteinas, B., Gao, Q., Jain, E., Mackay, A. G., Mitsopoulos, C., & Zvelebil, M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0945-5 · Cited by 26 · see citing works

Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling

Peifer, M., Weiss, J. M., Sos, M. L., Koker, M., Heynck, S., Netzer, C., Fischer, S., Rode, H. B., Rauh, D., Rahnenführer, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008919 · Cited by 24 · see citing works

Modeling of Protein Signaling Networks in Clinical ProteomicsPreprint

Geho, D. H., Petricoin, E. F., Liotta, L. A., & Araujo, R. P. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.022 · Cited by 20 · see citing works

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

Infante, J. R., Falchook, G. S., Lawrence, D. P., Weber, J. S., Kefford, R. F., Bendell, J. C., Kurzrock, R., Shapiro, G. I., Kudchadkar, R. R., Long, G. V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.cra8503 · Cited by 20 · see citing works

Enzyme kinetics and combination chemotherapy: An appraisal of current concepts

Harrap, K. R., & Jackson, R. (1975) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(75)90009-6 · Cited by 18 · see citing works

Personalized Medicine: Patient-Predictive Panel Power

Workman, P., Clarke, P. A., & Al‐Lazikani, B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.030 · Cited by 16 · see citing works

The combination of cytotoxic and molecularly targeted therapies – can it be done?

Jackman, A. L., Kaye, S. B., & Workman, P. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.11.012 · Cited by 16 · see citing works

Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?

Catalanotti, F., & Solit, D. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0626 · Cited by 14 · see citing works

A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib.

Falchook, G. S., Wheler, J. J., Naing, A., Hong, D. S., Moulder, S. L., Piha-Paul, S. A., Ng, C. S., Jackson, E., & Kurzrock, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2512 · Cited by 12 · see citing works

Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation

Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset

Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813 · see citing works

Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676 · see citing works

DeepSynergy: predicting anti-cancer drug synergy with Deep Learning

Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 651 · see citing works

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

Hallberg, B., & Palmer, R. H. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3580 · Cited by 643 · see citing works

A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy

Yi, H.-G., Jeong, Y. H., Kim, Y., Choi, Y.-J., Moon, H. E., Park, S. H., Kang, K. S., Bae, M., Jang, J., Youn, H., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0363-x · Cited by 634 · see citing works

SynergyFinder: a web application for analyzing drug combination dose–response matrix data

Ianevski, A., He, L., Aittokallio, T. A., & Tang, J. P. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 535 · see citing works

Polymeric Nanostructures for Imaging and Therapy

Elsabahy, M., Heo, G. S., Lim, S., Sun, G., & Wooley, K. L. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00135 · Cited by 507 · see citing works

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 508 · see citing works

Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions

Han, K., Jeng, E., Hess, G., Morgens, D., Li, A., & Bassik, M. (2017) · Nature Biotechnology · doi:10.1038/nbt.3834 · Cited by 482 · see citing works

Effective drug combinations in breast, colon and pancreatic cancer cells

Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04437-2 · Cited by 469 · see citing works

FAK signaling in human cancer as a target for therapeutics

Lee, B. Y., Timpson, P., Horvath, L. G., & Daly, R. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.10.001 · Cited by 431 · see citing works

Combine and conquer: challenges for targeted therapy combinations in early phase trials

Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394 · see citing works

The production of 3D tumor spheroids for cancer drug discovery

Sant, S., & Johnston, P. A. (2017) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2017.03.002 · Cited by 404 · see citing works

Evolutionary Determinants of Cancer

Greaves, M. F. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0439 · Cited by 411 · see citing works

Niosomes as Nanoparticular Drug Carriers: Fundamentals and Recent Applications

Seleci, D. A., Şeleci, M., Walter, J., Stahl, F., & Scheper, T. H. (2016) · Journal of Nanomaterials · doi:10.1155/2016/7372306 · Cited by 409 · see citing works

An unbiased oncology compound screen to identify novel combination strategies

O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0843 · Cited by 407 · see citing works

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

Griner, L. A. M., Guha, R., Shinn, P., Young, R. M., Keller, J. M., Liu, D., Goldlust, I. S., Yasgar, A., McKnight, C. G., Boxer, M. B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311846111 · Cited by 381 · see citing works

Nanoparticles for combination drug therapy

Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367 · see citing works

Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor

Yin, Q., Shen, J., Zhang, Z., Yu, H., & Li, Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.04.011 · Cited by 366 · see citing works

A Convergent Synthetic Platform for Single-Nanoparticle Combination Cancer Therapy: Ratiometric Loading and Controlled Release of Cisplatin, Doxorubicin, and Camptothecin

Liao, L., Liu, J., Dreaden, E. C., Morton, S. W., Shopsowitz, K. E., Hammond, P. T., & Johnson, J. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502011g · Cited by 365 · see citing works

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

Menden, M. P., Wang, D. Y. Q., Mason, M. J., Szalai, B., Bulusu, K. C., Guan, Y., Yu, T. V., Kang, J., Jeon, M., Wolfinger, R. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09799-2 · Cited by 360 · see citing works

Role of integrated cancer nanomedicine in overcoming drug resistance

Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343 · see citing works

Stimuli-sensitive nanopreparations for combination cancer therapy

Jhaveri, A. M., Deshpande, P. P., & Torchilin, V. P. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.002 · Cited by 335 · see citing works

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways

Yap, T. A., Omlin, A. G., & Bono, J. S. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 328 · see citing works

Independent Drug Action in Combination Therapy: Implications for Precision Oncology

Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 322 · see citing works

A community computational challenge to predict the activity of pairs of compounds

Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321 · see citing works

Predicting cellular responses to complex perturbations in high‐throughput screens

Lotfollahi, M., Klimovskaia Susmelj, A., De Donno, C., Hetzel, L., Ji, Y., Ibarra, I. L., Srivatsan, S. R., Naghipourfar, M., Daza, R. M., Martin, B., et al. (2023) · Molecular Systems Biology · doi:10.15252/msb.202211517 · Cited by 307 · see citing works

Formononetin: A Review of Its Anticancer Potentials and Mechanisms

Tay, K. C., Tan, L. T., Chan, C. K., Hong, S. L., Chan, K., Yap, W. H., Pusparajah, P., Lee, L., & Goh, B. H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00820 · Cited by 299 · see citing works

The Roles of MDM2 and MDMX in Cancer

Karni-Schmidt, O., Lokshin, M., & Prives, C. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 294 · see citing works

In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities

Rubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296 · see citing works

Supramolecular “Trojan Horse” for Nuclear Delivery of Dual Anticancer Drugs

Cai, Y., Shen, H., Zhan, J., Lin, M., Dai, L., Ren, C., Shi, Y., Liu, J., Gao, J., & Yang, Z. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12322 · Cited by 294 · see citing works

Towards targeting of shared mechanisms of cancer metastasis and therapy resistance

Weiß, F., Lauffenburger, D. A., & Friedl, P. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-021-00427-0 · Cited by 294 · see citing works

Artificial intelligence for drug discovery: Resources, methods, and applications

Chen, W., Liu, X., Zhang, S., & Chen, S. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.02.019 · Cited by 288 · see citing works

Upconversion nanocomposite for programming combination cancer therapy by precise control of microscopic temperature

Zhu, X., Li, J., Qiu, X., Liu, Y., Feng, W., & Li, F. (2018) · Nature Communications · doi:10.1038/s41467-018-04571-4 · Cited by 277 · see citing works

Rethinking the war on cancer

Hanahan, D. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62226-6 · Cited by 271 · see citing works

FLASH Radiotherapy: Current Knowledge and Future Insights Using Proton-Beam Therapy

Hughes, J. R., & Parsons, J. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186492 · Cited by 270 · see citing works

Concepts in Boolean network modeling: What do they all mean?

Schwab, J. D., Werle, S. D., Ikonomi, N., Kühl, M., & Kestler, H. A. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.001 · Cited by 249 · see citing works

Systems Pharmacology for Investigation of the Mechanisms of Action of Traditional Chinese Medicine in Drug Discovery

Zhang, W., Huai, Y., Miao, Z., Qian, A., & Wang, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00743 · Cited by 250 · see citing works

Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM

Wong, A. S. L., Choi, G. C. G., Cui, C. H., Pregernig, G., Milani, P., Adam, M., Perli, S. D., Kazer, S. W., Gaillard, A., Hermann, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517883113 · Cited by 236 · see citing works

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors

Kalin, J. H., Wu, M., Gómez, A. V., Song, Y., Das, J., Hayward, D., Adejola, N., Wu, M., Panova, I. P., Chung, H. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02242-4 · Cited by 238 · see citing works

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

de Castro, D. G., Clarke, P. A., Al‐Lazikani, B., & Workman, P. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.237 · Cited by 234 · see citing works

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening

Lin, G. L., Wilson, K. M., Ceribelli, M., Stanton, B. Z., Woo, P. J., Kreimer, S., Qin, E. Y., Zhang, X., Lennon, J., Nagaraja, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0064 · Cited by 230 · see citing works

DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy

Liu, H., Zhang, W., Zou, B., Wang, J., Deng, Y., & Deng, L. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1007 · Cited by 238 · see citing works

A microfluidics platform for combinatorial drug screening on cancer biopsies

Eduati, F., Utharala, R., Madhavan, D., Neumann, U. P., Longerich, T., Cramer, T., Saez-Rodriguez, J., & Merten, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04919-w · Cited by 239 · see citing works

Network Modeling of TGFβ Signaling in Hepatocellular Carcinoma Epithelial-to-Mesenchymal Transition Reveals Joint Sonic Hedgehog and Wnt Pathway Activation

Steinway, S. N., Zañudo, J. G. T., Ding, W., Rountree, C. B., Feith, D. J., Loughran, T. P., & Albert, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0225 · Cited by 230 · see citing works

Furin‐Mediated Sequential Delivery of Anticancer Cytokine and Small‐Molecule Drug Shuttled by Graphene

Jiang, T., Sun, W., Zhu, Q., Burns, N. A., Khan, S. A., Mo, R., & Gu, Z. (2014) · Advanced Materials · doi:10.1002/adma.201404498 · Cited by 228 · see citing works

Computational network biology: Data, models, and applications

Liu, C., Ma, Y.-F., Zhao, J., Nussinov, R., Zhang, Y.-C., Cheng, F., & Zhang, Z.-K. (2020) · Physics Reports · doi:10.1016/j.physrep.2019.12.004 · Cited by 201 · see citing works

Cell Fate Reprogramming by Control of Intracellular Network Dynamics

Zañudo, J. G. T., & Albert, R. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004193 · Cited by 222 · see citing works

Linking the future of anticancer metal-complexes to the therapy of tumour metastases

Bergamo, A., & Sava, G. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00134j · Cited by 220 · see citing works

Rational Cancer Treatment Combinations: An Urgent Clinical Need

Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 216 · see citing works

Targeting histone deacetylases for cancer therapy: Trends and challenges

Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222 · see citing works

Maximizing the Therapeutic Potential of HSP90 Inhibitors

Butler, L. M., Ferraldeschi, R., Armstrong, H., Centenera, M. M., & Workman, P. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0234 · Cited by 208 · see citing works

An omics perspective on drug target discovery platforms

Paananen, J., & Fortino, V. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz122 · Cited by 207 · see citing works

Co-encapsulation of resveratrol and curcumin in lipid-core nanocapsules improves their in vitro antioxidant effects

Coradini, K., Lima, F. O., Oliveira, C. M., Chaves, P. S., Athayde, M. L., Carvalho, L. M., & Beck, R. C. R. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.04.009 · Cited by 200 · see citing works

Threatening cancer with nanoparticle aided combination oncotherapy

Rawal, S. U., & Patel, M. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.015 · Cited by 204 · see citing works

Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer

Malyutina, A., Majumder, M. M., Wang, W., Pessia, A., Heckman, C. A., & Tang, J. P. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006752 · Cited by 199 · see citing works

Evolution of androgen receptor targeted therapy for advanced prostate cancer

Wong, Y. N. S., Ferraldeschi, R., Attard, G., & Bono, J. S. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.72 · Cited by 199 · see citing works

Large-scale exploration and analysis of drug combinations

Li, P., Huang, C., Fu, Y., Wang, J., Wu, Z., Ru, J., Zheng, C., Guo, Z., Chen, X., Zhou, W., et al. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv080 · Cited by 196 · see citing works

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189 · see citing works

MatchMaker: A Deep Learning Framework for Drug Synergy Prediction

Kuru, H. İ., Taştan, Ö., & Çiçek, A. E. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3086702 · Cited by 188 · see citing works

PEG- b -PLA micelles and PLGA- b -PEG- b -PLGA sol–gels for drug delivery

Cho, H., Gao, J., & Kwon, G. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.015 · Cited by 187 · see citing works

The pro-tumorigenic host response to cancer therapies

Shaked, Y. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0209-6 · Cited by 181 · see citing works

Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles

Tang, J. P., & Aittokallio, T. A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990470 · Cited by 184 · see citing works

Prediction of drug combination effects with a minimal set of experiments

Ianevski, A., Giri, A. K., Gautam, P., Kononov, A., Potdar, S., Saarela, J., Wennerberg, K., & Aittokallio, T. A. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0122-4 · Cited by 169 · see citing works

Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device

Khoo, B. L., Grenci, G., Lim, Y. B., Lee, S. C., Han, J., & Lim, C. T. (2018) · Nature Protocols · doi:10.1038/nprot.2017.125 · Cited by 172 · see citing works

Mitochondria and plasma membrane dual-targeted chimeric peptide for single-agent synergistic photodynamic therapy

Cheng, H. B., Zheng, R., Fan, G., Fan, J., Zhao, L., Jiang, X., Yang, B., Yu, X., Li, S., & Zhang, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.005 · Cited by 173 · see citing works

Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth

Yadav, V. K., & Talwar, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.119 · Cited by 172 · see citing works

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma

Wei, W., Shin, Y. S., Xue, M., Matsutani, T., Masui, K., Yang, H., Ikegami, S., Gu, Y., Herrmann, K., Johnson, D., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.012 · Cited by 169 · see citing works

Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy

Leary, M., Heerboth, S., LAPINSKA, K., & Sarkar, S. (2018) · Cancers · doi:10.3390/cancers10120483 · Cited by 166 · see citing works

Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue

Gote, V., Nookala, A. R., Bolla, P. K., & Pal, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094673 · Cited by 173 · see citing works

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

Lim, H.-J., Crowe, P., & Yang, J.-L. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1803-3 · Cited by 161 · see citing works

Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy

Domoto, T., Pyko, I. V., Furuta, T., Miyashita, K., Uehara, M., Shimasaki, T., Nakada, M., & Minamoto, T. (2016) · Cancer Science · doi:10.1111/cas.13028 · Cited by 159 · see citing works

The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells

Menéndez, J. A., Joven, J., Cufí, S., Corominas-Faja, B., Oliveras‐Ferraros, C., Cuyàs, E., Martı́n-Castillo, B., López‐Bonet, E., Alarcón, T., & Vázquez‐Martín, A. (2013) · Cell Cycle · doi:10.4161/cc.24479 · Cited by 158 · see citing works

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

Klempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148 · see citing works

A phase II trial of a multi‐agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

Robison, N. J., Campigotto, F., Chi, S. N., Manley, P. E., Turner, C. D., Zimmerman, M. A., Chordas, C. A., Werger, A. M., Allen, J. C., Goldman, S., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24794 · Cited by 151 · see citing works

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

Banerji, U., Dean, E. J., Fidalgo, J. A. P., Batist, G., Bedard, P. L., You, B., Westin, S. N., Kabos, P., Garrett, M. D., Tall, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2260 · Cited by 151 · see citing works

Epigenetic polypharmacology: from combination therapy to multitargeted drugs

de Lera, Á. R., & Ganesan, A. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0271-9 · Cited by 148 · see citing works

Two-dimensional transition metal dichalcogenide nanomaterials for combination cancer therapy

Gong, L., Yan, L., Zhou, R., Xie, J., Wu, W., & Gu, Z. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00195a · Cited by 144 · see citing works

Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases

Dheer, D., Nicolas, J., & Shankar, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.010 · Cited by 144 · see citing works

A public-private partnership to unlock the untargeted kinome

Knapp, S., Arruda, P., Blagg, J., Burley, S. K., Drewry, D. H., Edwards, A. M., Fabbro, D., Gillespie, P., Gray, N. S., Küster, B., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1113 · Cited by 141 · see citing works

Current Advances in Black Phosphorus‐Based Drug Delivery Systems for Cancer Therapy

Liu, W., Dong, A., Wang, B., & Zhang, H. (2021) · Advanced Science · doi:10.1002/advs.202003033 · Cited by 138 · see citing works

Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer

Huang, H., Mallidi, S., Liu, J., Chiang, C.-T., Mai, Z., Goldschmidt, R., Ebrahim-Zadeh, N., Rizvi, I., & Hasan, T. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0391 · Cited by 139 · see citing works

Combination antitumor therapy with targeted dual-nanomedicines

Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 139 · see citing works

Tumor Microenvironment Responsive Drug‐Dye‐Peptide Nanoassembly for Enhanced Tumor‐Targeting, Penetration, and Photo‐Chemo‐Immunotherapy

Peng, J., Yang, Q., Xiao, Y., Shi, K., Liu, Q., Hao, Y., Yang, F., Han, R., & Qian, Z. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201900004 · Cited by 139 · see citing works

Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK

Tolcher, A. W., Khan, K. H., Ong, M., Banerji, U., Papadimitrakopoulou, V. A., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1901 · Cited by 137 · see citing works

Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy

Xiao, B., Ma, L., & Merlin, D. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1205583 · Cited by 138 · see citing works

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity

Palmer, A. C., Chidley, C., & Sorger, P. K. (2018) · eLife · doi:10.7554/elife.50036 · Cited by 136 · see citing works

Targeting Carbonic Anhydrase IX Activity and Expression

Mahon, B. P., Pinard, M. A., & McKENNA, R. V. (2015) · Molecules · doi:10.3390/molecules20022323 · Cited by 135 · see citing works

Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer

Sun, Y., Sheng, Z., Ma, C., Tang, K., Zhu, R., Wu, Z., Shen, R., Feng, J. H., Wu, D., Huang, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms9481 · Cited by 134 · see citing works

Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine

Kamel, H. F. M., & Al-Amodi, H. S. A. B. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.11.005 · Cited by 134 · see citing works

Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines

Li, C., Jia, W., Yang, J., Cheng, C., & Olaleye, O. E. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00983-7 · Cited by 133 · see citing works

Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling

Flobak, Å., Baudot, A., Rémy, É., Thommesen, L., Thieffry, D., Kuiper, M. T. R., & Lægreid, A. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004426 · Cited by 132 · see citing works

Objective assessment of cancer genes for drug discovery

Patel, M. N., Halling‐Brown, M., Tym, J. E., Workman, P., & Al‐Lazikani, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3913 · Cited by 130 · see citing works

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression

Rusan, M., Li, K., Li, Y. Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N. P., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 128 · see citing works

Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy

Zhang, P., Li, J., Ghazwani, M., Zhao, W., Huang, Y., Zhang, X., Venkataramanan, R., & Song, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.027 · Cited by 131 · see citing works

Mechanism-Independent Optimization of Combinatorial Nanodiamond and Unmodified Drug Delivery Using a Phenotypically Driven Platform Technology

Wang, H., Lee, D.-K., Chen, K., Chen, J.-Y., Zhang, K., Silva, A., Ho, C., & Ho, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b00638 · Cited by 129 · see citing works

Multi-drug delivery nanocarriers for combination therapy

Gadde, S. (2015) · MedChemComm · doi:10.1039/c5md00365b · Cited by 127 · see citing works

Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane

Fu, Q., Lv, P., Chen, Z.-K., Ni, D., Zhang, L., Yue, H., Yue, Z., Wei, W., & Ma, G. (2015) · Nanoscale · doi:10.1039/c4nr07027e · Cited by 128 · see citing works

New strategies for targeting drug combinations to overcome mutation-driven drug resistance

Wang, L., Wang, H., Song, D., Xu, M., & Liebmen, M. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.002 · Cited by 30 · see citing works

Rational combinations of targeted cancer therapies: background, advances and challenges

Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503 · see citing works

New rational design approach to optimize combination therapy strategies

Jones, B. L. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.248 · Cited by 1 · see citing works

Combinatorial Approaches to Treat Cancer

(2021) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789814998666121010009 · Cited by 1 · see citing works

Combined Therapy in Cancer: The Non-coding Approach

Gulei, D., & Berindan‐Neagoe, I. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.013 · Cited by 9 · see citing works